MGX Metagenomi, Inc. Common Stock
Healthcare$1.36+0.74%ClosedMarket Cap: $51.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.37
P/S
2.28
EV/EBITDA
-0.76
DCF Value
$-91.46
FCF Yield
-172.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-12.5%
Operating Margin
-415.5%
Net Margin
-384.6%
ROE
-51.2%
ROA
-43.6%
ROIC
-51.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.2M | 100.0% | $-24.6M | $-23.1M | $— | — |
| Q4 null | $3.9M | 66.8% | $-24.4M | $-22.5M | $— | — |
| FY null | $25.2M | 78.9% | $-96.0M | $-87.9M | $— | — |
| Q3 null | $8.7M | 84.7% | $-22.8M | $-20.4M | $— | — |
| Q2 null | $8.5M | -164.4% | $-21.0M | $-19.9M | $— | — |
| Q1 null | $4.1M | 100.0% | $-27.8M | $-25.0M | $— | — |
| Q4 null | $9.6M | 100.0% | $-20.6M | $-23.4M | $— | — |
| FY null | $52.3M | 100.0% | $-88.9M | $-78.1M | $— | — |
| Q3 null | $11.5M | 100.0% | $-22.4M | $-18.8M | $— | — |
| Q2 null | $20.0M | 100.0% | $-16.9M | $-10.7M | $— | — |
| Q1 null | $11.2M | -181.7% | $-29.0M | $-25.1M | $— | — |
| Q4 2023 | $12.4M | -99.7% | $-20.2M | $-19.3M | $-0.51 | — |